STR-0011

STR-0011 is a non-engineered, non-pathogenic oncolytic virus being developed by SATOR Therapeutics as its lead clinical candidate. It is currently in IND-enabling studies for the treatment of mesothelioma, an orphan indication, and is also being explored for glioblastoma multiforme (GBM). Preclinical studies have demonstrated that STR-0011 significantly reduces tumor progression and outperforms existing oncolytic therapies like T-Vec in mesothelioma models. The virus is designed for systemic administration via intravenous injection and works by selectively infecting and lysing tumor cells while potentially stimulating a broader anti-tumor immune response.